/PRNewswire/ TATAA Biocenter, a leading provider of high-quality molecular analysis services, announced today that it has become a certified Qualified.
US regulators have approved the first-in-class drug efgartigimod for the treatment of the rare muscle disease generalized myasthenia gravis, opening up its developer argenx to billion-dollar revenues.